(Q37315451)

English

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia

scientific article published on 21 September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

chronic schizophrenia

1 reference

based on heuristic

inferred from title

Robert A. Rosenheck

3

object named as

Robert A Rosenheck

1 reference

Europe PubMed Central

19 August 2017

PMC publication ID

Jeffrey Lieberman

8

object named as

Jeffrey A Lieberman

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Donald E Addington

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Somaia Mohamed

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sonia M Davis

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Thomas Scott Stroup

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Joseph P McEvoy

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Marvin S Swartz

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

publication date

21 September 2010

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

The Journal of Clinical Psychiatry

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

72

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

75-80

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Atypical antipsychotics for people with both schizophrenia and depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

The mesolimbic dopamine reward circuit in depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Schizophrenia and suicide: systematic review of risk factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Schizophrenia and deliberate self-harm: a systematic review of risk factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Treatment of schizoaffective disorder and schizophrenia with mood symptoms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

14 September 2017

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

28 September 2017

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

28 September 2017

Depressive symptoms in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

26 June 2018

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

26 June 2018

Specificity of the Calgary Depression Scale for schizophrenics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

26 June 2018

Importance of Psychiatric Diagnosis in Prediction of Clinical Drug Effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

26 June 2018

Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia--findings from an in vivo SPECT study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of four scales measuring depression in schizophrenic inpatients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing depression in schizophrenia: the Calgary Depression Scale

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depression in schizophrenia: a comparison of three measures

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency and differential diagnosis of depressive syndromes in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reliability and validity of a depression rating scale for schizophrenics

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4088/JCP.09M05258GRE

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37315451&oldid=2071484970"